Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.48 |
| ▸ | PPARA | Q07869 | 4/20 | 0.48 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4026331 | 0.85 | PPARG (0.65) | PPARGPPARASMPD1HDAC6SIGMAR1 | |
| SCHEMBL4032932 | 0.81 | MAPT (0.51) | PPARGPPARAHDAC6ALDH1A1MEN1 | |
| SCHEMBL4028561 | 0.80 | PPARG (0.53) | PPARGPPARASMPD1ALDH1A1MEN1 | |
| SCHEMBL6003664 | 0.79 | PPARG (0.76) | PPARGPPARAPPARD | |
| SCHEMBL4028562 | 0.78 | PPARG (0.43) | PPARGPPARAPTGS1PTGS2ALDH1A1 | |
| SCHEMBL6003721 | 0.77 | PPARG (0.62) | PPARGPPARAMAPTPPARD | |
| SCHEMBL4032368 | 0.76 | PPARG (0.63) | PPARGPPARASMPD1ALDH1A1MEN1 | |
| SCHEMBL4031056 | 0.76 | PPARG (0.50) | PPARGPPARASMPD1ALDH1A1MEN1 | |
| Tert-Butylamine SCHEMBL6277645 | 0.76 | PPARG (0.71) | PPARGPPARAPPARD | |
| SCHEMBL4029861 | 0.75 | PPARG (0.48) | PPARGPPARAALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569916-B1 | SUBSTITUTED ARALKYL DERIVATIVES | CADILA HEALTHCARE LTD (IN) | 2009-01-07 | — | — | EP | claimed |
| US-20060142277-A1 | Substituted aralkyl derivatives | CADILA HEALTHCARE LIMITED | 2006-06-29 | — | — | US | claimed |
| EP-1569916-A1 | SUBSTITUTED ARALKYL DERIVATIVES | CADILA HEALTHCARE LTD. (IN) | 2005-09-07 | — | — | EP | claimed |
| WO-2004046119-A1 | SUBSTITUTED ARALKYL DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2004-06-03 | — | — | WO | claimed |
| EP-1569916-B1 | SUBSTITUTED ARALKYL DERIVATIVES | CADILA HEALTHCARE LTD (IN) | 2009-01-07 | — | — | EP | disclosed |
| US-20060142277-A1 | Substituted aralkyl derivatives | CADILA HEALTHCARE LIMITED | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142277-A1 | Substituted aralkyl derivatives | UGT1A7, UGT1A10, UGT2B7 | PPARG 2043/4885PPARA 2339/4885SMPD1 3354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.